DK4010322T3 - Faste former af (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl) amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamid og anvendelser heraf - Google Patents

Faste former af (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl) amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamid og anvendelser heraf

Info

Publication number
DK4010322T3
DK4010322T3 DK19758589.6T DK19758589T DK4010322T3 DK 4010322 T3 DK4010322 T3 DK 4010322T3 DK 19758589 T DK19758589 T DK 19758589T DK 4010322 T3 DK4010322 T3 DK 4010322T3
Authority
DK
Denmark
Prior art keywords
tetrahydronapthalen
neopentylamino
pentanamide
propan
imidazol
Prior art date
Application number
DK19758589.6T
Other languages
English (en)
Inventor
Elaine Greer
Stephen Anderson
Mark Maloney
Shu Yu
Ekaterina Albert
Emily Rigsbee
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK4010322T3 publication Critical patent/DK4010322T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK19758589.6T 2019-08-09 2019-08-09 Faste former af (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl) amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamid og anvendelser heraf DK4010322T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/045948 WO2021029854A1 (en) 2019-08-09 2019-08-09 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Publications (1)

Publication Number Publication Date
DK4010322T3 true DK4010322T3 (da) 2025-12-15

Family

ID=67734850

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19758589.6T DK4010322T3 (da) 2019-08-09 2019-08-09 Faste former af (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl) amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamid og anvendelser heraf

Country Status (21)

Country Link
EP (2) EP4722197A1 (da)
JP (1) JP7608435B2 (da)
KR (1) KR102772889B1 (da)
CN (1) CN114555562A (da)
AR (1) AR119614A1 (da)
AU (1) AU2019461090B2 (da)
BR (1) BR112022002392A2 (da)
CA (1) CA3150424A1 (da)
CO (1) CO2022002731A2 (da)
DK (1) DK4010322T3 (da)
FI (1) FIC20260011I1 (da)
HR (1) HRP20251641T1 (da)
IL (1) IL290428A (da)
LT (1) LT4010322T (da)
MX (1) MX2022001743A (da)
NL (1) NL301374I2 (da)
NO (1) NO2026017I1 (da)
PE (1) PE20221252A1 (da)
PT (1) PT4010322T (da)
RS (1) RS67562B1 (da)
WO (1) WO2021029854A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916188A (zh) * 2020-03-13 2023-04-04 斯普林渥克斯治疗有限公司 尼罗司他与bcma定向疗法的组合疗法及其用途
MX2024002590A (es) 2021-09-01 2024-03-22 Springworks Therapeutics Inc Sintesis de nirogacestat.
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
EP4436958A1 (en) 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Solid state forms of nirogacestat salts
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途
JP2026508907A (ja) 2023-03-09 2026-03-13 ▲蘇▼州科睿思制▲葯▼有限公司 ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途
WO2026018210A1 (en) 2024-07-19 2026-01-22 Assia Chemical Industries Ltd. Solid state forms of nirogacestat dihydrochloride salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019053727A1 (en) * 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH

Also Published As

Publication number Publication date
CN114555562A (zh) 2022-05-27
LT4010322T (lt) 2025-12-29
MX2022001743A (es) 2022-05-10
BR112022002392A2 (pt) 2022-04-26
PE20221252A1 (es) 2022-08-16
EP4010322B1 (en) 2025-11-05
EP4010322A1 (en) 2022-06-15
NL301374I2 (nl) 2026-07-13
AR119614A1 (es) 2021-12-29
CO2022002731A2 (es) 2022-05-20
HRP20251641T1 (hr) 2026-02-13
AU2019461090A1 (en) 2022-03-17
EP4722197A1 (en) 2026-04-08
PT4010322T (pt) 2025-12-16
KR102772889B1 (ko) 2025-02-26
AU2019461090B2 (en) 2026-06-18
JP2022553479A (ja) 2022-12-23
IL290428A (en) 2022-07-01
RS67562B1 (sr) 2026-01-30
FIC20260011I1 (fi) 2026-04-07
WO2021029854A1 (en) 2021-02-18
KR20220062510A (ko) 2022-05-17
JP7608435B2 (ja) 2025-01-06
NO2026017I1 (no) 2026-03-26
CA3150424A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
PL4010322T3 (pl) Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie
LT4010322T (lt) (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA55301A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
MA56191A (fr) Inhibiteurs de l'autophagie à base d'amide d'aminopyrimidine et leurs procédés d'utilisation
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
CN111601791A (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
EP3911640A4 (en) PCSK9 INHIBITORS AND METHODS OF USE THEREOF
MA52963A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
EP3880685A4 (en) INHIBITORS OF ARG1 AND/OR ARG2
EP3645063A4 (en) SILK HYALURONIC ACID TISSUE FILLERS AND METHOD OF USING THEREOF
EP3962481A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
IL284799A (en) Tyk2 inhibitors and uses thereof
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP3810615A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
EP3765006A4 (en) ARGINASE INHIBITORS AND METHODS OF USE
EP3609864C0 (en) Hdac6 inhibitors and imaging agents
EP3947351A4 (en) SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE
EP3735242A4 (en) METALLO-BETA-LACTAMASE INHIBITORS AND METHOD OF USING THEREOF
IL310209A (en) ROCK2 inhibitors and their uses
IL290087B2 (en) Modified aminoheteroaryls and their use as DES1 inhibitors and/or antifibrotic agents
PE20241348A1 (es) Sintesis de nirogacestat
EP3996704A4 (en) COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS
EP3463366A4 (en) TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHOD FOR USE THEREOF